ONYX-015 engineered adenovirus that replicates in and kills tumor cells deficient in p53 data

ONXX announced that Phase I results in 32 patients show tolerability with no

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE